


Diagnostics

Kit for the diagnosis of patients suffering cord and/or lung cancer

A research group of the Andalusian Public Health System, in collaboration with the Spanish National Research Council (CSIC) and the University of Seville, has developed a kit for the diagnosis, prognosis and subclassification of patients suffering chronic obstructive respiratory disease (CORD) and/or lung cancer.

Oficina de **TRANSFERENCIA DE TECNOLOGÍA**
Sistema Sanitario Público de Andalucía



Description

Worldwide, lung cancer is the most common cause of cancer-related death. The main cause for developing lung cancer is long-term exposure to tobacco smoke. On the other hand, tobacco smoking is also responsible for developing further pathologies such as the chronic obstructive respiratory disease (CORD). The risk of lung cancer in patients with COPD is two- to fivefold greater compared with smokers without COPD. However, currently there is no a reliable method for the prediction, diagnostic and/or prognostic which allows the classification of patients suffering these diseases.

Some studies suggest that inflammation may be one of the main processes involved in the pathogenesis of both diseases. Several studies carried out in patients with CORD suggest that the levels of some pro-inflammatory cytokines and chemokines are increased when compared with healthy subjects. Additionally, the role of cytokines in lung cancer has been reported in numerous studies. Despite the advances made in this field, these results are insufficient to explain the role that inflammation plays in both pathologies as well as the possible pathways which are common or independent between both diseases.

The research group has developed a kit based on the analysis of some selected cytokines and growth factors for the diagnosis and prognosis which would allow professionals to classify patients depending on their pathology and, thus, to select the best treatment in a case by case basis. Additionally, the treatment monitoring for each patient is improved when this method and/or diagnostic kit is used. These studies were validated in 359 patients.

1. The method facilitates the professionals work enabling a reliable diagnosis, prognosis and/or classification of patients suffering CORD and/or lung cancer.
2. The use of the diagnostic kit based on this method offers a new tool for selecting the best possible treatment depending on the diagnosis.
3. The method also allows an improved monitoring of the patient prognosis as well as a tool to determine whether the prescribed treatment is being effective.



Intellectual Property

This technology is covered by a priority Spanish patent application with the possibility of international extension.



Aims

We are looking for a partner interested in a license and/ or a collaboration agreement to further develop and exploit this innovative technology.



Classification

Area: Diagnostic
Pathology: Cancer or Oncology / Respiratory & Pulmonar System.



Advantages



JUNTA DE ANDALUCÍA
CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES



INSTITUTO DE INVESTIGACIONES BIOMÉDICAS DE SEVILLA



Fundación Pública
Andaluza para la Gestión de la
Investigación en Salud de Sevilla

Hospital Universitario Virgen del Rocío. Edificio de Laboratorios, 6ª Planta. Avda. Manuel Siurot, s/n 41013 Sevilla. ESPAÑA ☎ +34 955 013 647 📞 +34 671 597 574

✉ pablo.hervas.exts@juntadeandalucia.es